SARS-CoV-2 IgG Levels Allow Predicting the Optimal Time Span of Convalescent Plasma Donor Suitability

Convalescent plasma (CP) has been in use for the treatment of numerous infectious diseases for more than a century, recently also for coronavirus disease 2019 (COVID-19). A major challenge for this treatment is identifying suitable donors with sufficient levels of functional antibodies and to determ...

Full description

Saved in:
Bibliographic Details
Published inDiagnostics (Basel) Vol. 12; no. 11; p. 2567
Main Authors Laner-Plamberger, Sandra, Lindlbauer, Nadja, Weidner, Lisa, Gänsdorfer, Simon, Weseslindtner, Lukas, Held, Nina, Lauth, Wanda, Zimmermann, Georg, Kern, Jan Marco, Föttinger, Fabian, Ombres, Laura, Jungbauer, Christof, Rohde, Eva, Grabmer, Christoph
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 22.10.2022
MDPI
Subjects
Antibodies
Blood donors
Blood groups
Blood tests
convalescent plasma
Coronaviruses
COVID-19
COVID-19 vaccines
Creatinine
Enzymes
Health aspects
Immunization
Immunoglobulin G
Immunoglobulins
Infectious diseases
Influenza
Medical screening
Methods
Plasma
plasmapheresis
Proteins
SARS-CoV-2 antibodies
Severe acute respiratory syndrome coronavirus 2
Software
Austria
United States > US
Online AccessGet full text

Cover

More Information
Summary:Convalescent plasma (CP) has been in use for the treatment of numerous infectious diseases for more than a century, recently also for coronavirus disease 2019 (COVID-19). A major challenge for this treatment is identifying suitable donors with sufficient levels of functional antibodies and to determine the optimal time span for CP donation. In this retrospective study, we analyzed 189 CP donations of 66 donors regarding anti-SARS-CoV-2 anti-S IgG antibody levels. We found a significant correlation between the semi-quantitative SARS-CoV-2 IgG ratio values and in vitro antibody functionality. A time-to-event analysis allowed us to predict the optimal time span of COVID-19 CP donor suitability. We found that high IgG ratio values, which significantly correlate with high in vitro antibody functionality, were suitable for CP donation for a median of 134 days after the first CP donation. Donors with lower IgG ratios were suitable for a median of 53 days. Our data support plasma collection centers to determine optimal points in time for CP donation by means of widely used semi-quantitative laboratory IgG ratio values.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2075-4418
2075-4418
DOI:10.3390/diagnostics12112567